| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-6005915 |
| Email: |
sales@picasso-e.com |
| Products Intro: |
Product Name:Cog 133 trifluoroacetate
CAS:2828432-37-5
Purity:98% Package:100mg;250mg;1g
|
| Company Name: |
Adooq Bioscience LLC
|
| Tel: |
400-025-6535 |
| Email: |
sales@adooq.cn |
| Products Intro: |
Product Name:COG 133 TFA
CAS:2828432-37-5
|
|
| | Cog 133 trifluoroacetate Basic information |
| | Cog 133 trifluoroacetate Chemical Properties |
| form | Solid | | color | White to off-white | | Sequence | Ac-Leu-Arg-Val-Arg-Leu-Ala-Ser-His-Leu-Arg-Lys-Leu-Arg-Lys-Arg-Leu-Leu-NH2 |
| | Cog 133 trifluoroacetate Usage And Synthesis |
| Uses | COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC50 of 445 nM[1][2]. | | in vivo | COG 133 (1 mg/kg; intratracheal administration; every other day; for 4 weeks) treatment impairs the resolution of pulmonary fibrosis in mice[3]. | Animal Model: | Male C57BL/6 mice (6-week-old) instilled with Bleomycin[3] | | Dosage: | 1 mg/kg
| | Administration: | Intratracheal administration; every other day; for 4 weeks | | Result: | Did blunt the resolution of lung fibrosis. |
| | References | [1] Orleancio Gomes R Azevedo, et al. Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. BMC Gastroenterol. 2012 Jul 13;12:35. DOI:10.1186/1471-230X-12-35
[2] Elaine A Gay, et al. Apolipoprotein E-derived peptides block alpha7 neuronal nicotinic acetylcholine receptors expressed in xenopus oocytes. J Pharmacol Exp Ther. 2006 Feb;316(2):835-42. DOI:10.1124/jpet.105.095505
[3] Huachun Cui, et al. Monocyte-derived alveolar macrophage apolipoprotein E participates in pulmonary fibrosis resolution. JCI Insight. 2020 Mar 12;5(5):e134539. DOI:10.1172/jci.insight.134539 |
| | Cog 133 trifluoroacetate Preparation Products And Raw materials |
|